Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Pediatric High Grade Glioma and Ependymoma
NCT01462695Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2012
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in high-grade glioma (HGG) and ependymoma, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 8 weeks. Started Jan 2012; status: completed.
02
Drugs
sunitinib
03
Conditions
high-grade glioma (HGG)ependymoma
Beyond the preview
Go deeper on NCT01462695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01462695.